A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)

Alex Dyson; Megan Ryan; Shruti Garg; D. Gareth Evans; Richard A. Baines

doi:10.1101/2022.11.11.516139

A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)

Alex Dyson, Megan Ryan, Shruti Garg, D. Gareth Evans, Richard A. Baines

Research output: Other contribution › peer-review

Original language	Undefined
DOIs	https://doi.org/10.1101/2022.11.11.516139
Publication status	Published - 13 Nov 2022

Access to Document

10.1101/2022.11.11.516139

Cite this

@misc{4d25a96078e3471982e35db5473ef77d,

title = "A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)",

author = "Alex Dyson and Megan Ryan and Shruti Garg and Evans, {D. Gareth} and Baines, {Richard A.}",

year = "2022",

month = nov,

day = "13",

doi = "10.1101/2022.11.11.516139",

language = "Undefined",

type = "Other",

}

TY - GEN

T1 - A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)

AU - Dyson, Alex

AU - Ryan, Megan

AU - Garg, Shruti

AU - Evans, D. Gareth

AU - Baines, Richard A.

PY - 2022/11/13

Y1 - 2022/11/13

UR - https://doi.org/10.1101/2022.11.11.516139

U2 - 10.1101/2022.11.11.516139

DO - 10.1101/2022.11.11.516139

M3 - Other contribution

ER -

A targeted, low-throughput compound screen in aDrosophilamodel of neurofibromatosis type 1 identifies simvastatin and BMS-204352 as potential therapies for autism spectrum disorder (ASD)

Access to Document

Other files and links

Cite this